Oxymorphone and oxymorphone extended release: A pharmacotherapeutic review

Journal of Opioid Management

Volumn 4, Issue 3, 2008, Pages 131-144

  Sloan, Paul Alexander ^a   Barkin, Robert L ^b  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

Author keywords

Analgesics; Opioids; Oxymorphone; Pain management; Pharmacodynamics; Pharmacokinetics

Indexed keywords

FENTANYL; MORPHINE; NARCOTIC ANALGESIC AGENT; OXYCODONE; OXYMORPHONE; PLACEBO;

ALCOHOLIC BEVERAGE; ANALGESIC ACTIVITY; CANCER PAIN; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DIZZINESS; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG RELEASE; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; EUPHORIA; FOOD DRUG INTERACTION; GASTROINTESTINAL MOTILITY; HUMAN; LABORATORY TEST; LIPID DIET; LOW BACK PAIN; NAUSEA; NONHUMAN; OSTEOARTHRITIS; PAIN ASSESSMENT; PHARMACODYNAMICS; PHYSICAL EXAMINATION; POSTOPERATIVE PAIN; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RESPIRATION DEPRESSION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TOXICITY TESTING; TREATMENT DURATION; URINALYSIS; VITAL SIGN; VOMITING; WITHDRAWAL SYNDROME;

EID: 48449091303     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2008.0018     Document Type: Review

References (63)

1. American Pain Foundation: Pain facts and figures. Available at http://www.painfoundation.org/page.asp?file=Newsroom/ PainFacts.htm. Accessed March 6, 2008.
2. AGS Panel on Persistent Pain in Older Persons: The management of persistent pain in older persons. J Am Geriatr Soc. 2002; 50(6 suppl):S205-S224.
3. World Health Organization: Cancer Pain Relief. Geneva, Switzerland: WHO Office of Publication, 1996.
4. Sloan P, Babul N: Extended-release opioids for the management of chronic non-malignant pain. Expert Opin Drug Deliv. 2006; 3(4): 489-497.
5. American Pain Society: Guideline for the Management of Pain in Osteoarthritis, Rheumatoid Arthritis and Juvenile Chronic Arthritis. Chicago, IL: American Pain Society, 2002.
6. Coluzzi F, Pappagallo M: Opioid therapy for chronic noncancer pain: Practice guidelines for initiation and maintenance of therapy. Minerva Anestesiol. 2005; 71(7/8): 425-433.
7. Vallerand AH: The use of long-acting opioids in chronic pain management. Nurs Clin North Am. 2003; 38(3): 435-445.
8. Airaksinen O, Brox JI, Cedraschi C, et al.: Chapter 4. European guidelines for the management of chronic nonspecific low back pain. Eur Spine J. 2006; 15 (suppl 2): S192-S300.
9. McCarberg BH, Barkin RL: Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther. 2001; 8(3): 181-186.
10. Sloan P, Hamann S: Ultra low-dose opioid antagonists to enhance opioid analgesia. J Opioid Manage. 2006; 2(5): 295-304.
11. Nielsen CK, Ross FB, Shahrdad L, et al.: Oxycodone and morphine have distinctly different pharmacological profiles: Radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain. 2007; 132: 289-300.
12. Lotsch J, Geisslinger G: Relevance of frequent mu-opioid receptor polymorphisms for opioid activity in healthy volunteers. Pharmacogenomics J. 2006; 6(3): 200-210.
13. Lotsch J, Skarke C, Liefhold J, et al.: Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet. 2004; 43(14): 983-1013.
14. Pan L, Xu J, Yu R, et al.: Identification and characterization of six new alternatively spliced variants of the human mu opioid receptor gene, Oprm. Neuroscience. 2005; 133(1): 209-220.
15. Pan YX, Xu J, Mahurter L, et al.: Identification and characterization of two new human mu opioid receptor splice variants, hMOR-1O and hMOR-1X. Biochem Biophys Res Commun. 2003; 301(4): 1057-1061.
16. Pasternak DA, Pan L, Xu J, et al.: Identification of three new alternatively spliced variants of the rat mu opioid receptor gene: Dissociation of affinity and efficacy. J Neurochem. 2004; 91(4): 881-890.
17. Clarke S, Kitchen I: Opioid analgesia: new information from gene knockout studies. Curr Opin Anaesthesiol. 1999; 12(5): 609-614.
18. Ravert HT, Bencherif B, Madar I, et al.: PET imaging of opioid receptors in pain: progress and new directions. Curr Pharm Des. 2004; 10(7): 759-768.
19. Grilo RM, Bertin P, Scotto di Fazano C, et al.: Opioid rotation in the treatment of joint pain. A review of 67 cases. Joint Bone Spine. 2002; 69(5): 491-494.
20. Mercadante S, Bruera E: Opioid switching: A systematic and critical review. Cancer Treat Rev. 2006; 32(4): 304-315.
21. Quang-Cantagrel ND, Wallace MS, Magnuson SK: Opioid substitution to improve the effectiveness of chronic noncancer pain control: A chart review. Anesth Analg. 2000; 90(4): 933-937.
22. Barkin RL, Iusco AM, Barkin SJ: Opioids used in primary care for the management of pain: A pharmacologic, pharmacotherapeutic, and pharmacodynamic overview. In Boswell MV CB (ed): Weiner's Pain Management: A Practical Guide for Clinicians, 7th ed. New York: Taylor & Francis, 2006.
23. Weiss U: Derivatives of morphine. I. 14-hydroxydihydromorphine. Am J Chem Soc. 1955; 77: 5891-5892.
24. O'Neil MJ, ed: The Merck Index, 13 ed. Whitehouse Station, NJ: Merck & Co., 2001.
25. Poyhia R, Seppala T: Liposolubility and protein binding of oxycodone in vitro. Pharmacol Toxicol. 1994; 74(1): 23-27.
26. Fand I, Sinatra R: Whole body autoradiographic localization of C[14] labeled morphine and nalorphine. Anat Rec. 1978; 190: 392-393.
27. Kadian® (morphine sulfate sustained release capsules). Full Prescribing Information. Piscataway, NJ: Alpharma, 2004.
28. OxyContin® (oxycodone HCl controlled-release tablets). Full Prescribing Information, Purdue Pharma L.P., Stamford, CT, 2005.
29. OPANA® ER (oxymorphone hydrochloride extended-release tablets). Full Prescribing Information, Endo Pharmaceuticals Inc, Chadds Ford, PA, 2007.
30. Hermens JM, Ebertz JM, Hanifin JM, et al.: Comparison of histamine release in human skin mast cells induced by morphine, fentanyl, and oxymorphone. Anesthesiology. 1985; 62(2): 124-129.
31. Metzger TG, Paterlini MG, Ferguson DM, et al.: Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus. J Med Chem. 2001; 44(6): 857-862.
32. Ross FB, Smith MT: The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain. 1997; 73(2): 151-157.
33. Leighton GE, Hill RG, Hughes J: Effects of 5-HT and alpha 1 adrenoceptor antagonists on kappa opioid-induced sedation. Pharmacol Biochem Behav. 1988; 31(4): 899-904.
34. Kieffer BL, Gaveriaux-Ruff C: Exploring the opioid system by gene knockout. Prog Neurobiol. 2002; 66(5): 285-306.
35. Knoll AT, Meloni EG, Thomas JB, et al.: Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats. J Pharmacol Exp Ther. 2007; 323(3): 838-845.
36. Fichna J, Staniszewska R, Poels J, et al.: Mu-opioid receptor ligands lack receptor subtype selectivity in the aequorin luminescence-based calcium assay. Chem Biol Drug Des. 2007; 70(3): 247-253.
37. Wolozin BL, Pasternak GW: Classification of multiple morphine and enkephalin binding sites in the central nervous system. Proc Natl Acad Sci U S A. 1981; 78(10): 6181-6185.
38. Pasternak GW: Multiple opiate receptors: déjà vu all over again. Neuropharmacology. 2004; 47: 312-323.
39. Watanabe H, Nakayama D, Ito K, et al.: A Tyr-W-MIF-1 analog containing D-Pro2 acts as a selective mu2-opioid receptor antagonist in the mouse. J Pharmacol Exp Ther. 2005; 312(3): 1075-1081.
40. Pasternak GW: Opiate, enkephalin, and endorphin analgesia: relations to a single subpopulation of opiate receptors. Neurology. 1981; 31(10): 1311-1315.
41. Gintzler AR, Pasternak GW: Multiple mu receptors: Evidence for mu2 sites in the guinea pig ileum. Neurosci Lett. 1983; 39(1): 51-56.
42. OPANA (oxymorphone hydrochloride). Full Prescribing Information, Endo Pharmaceuticals Inc., Chadds Ford, PA, 2007.
43. Adams MP, Ahdieh H: Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. Drugs R D. 2005; 6(2): 91-99.
44. Adams MP, Ahdieh H: Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. Pharmacotherapy. 2004; 24(4): 468-476.
45. Aqua K, Gimbel J, Singla N, et al.: Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial. Clin Ther. 2007; 29(6): 1000-1012.
46. Gimbet J, Ahdieh H: The efficacy and safety of oral immediate-release oxymorphone for postsurgical pain. Anesth Analg. 2004; 99(5): 1472-1477.
47. Thirlwell MP, Sloan PA, Maroun JA, et al.: Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients. Cancer. 1989; 63(11 suppl): 2275-2283.
48. Leow KP, Smith MT, Watt JA, et al.: Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. Ther Drug Monit. 1992; 14(6): 479-484.
49. Leow KP, Smith MT, Williams B, et al.: Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clin Pharmacol Ther. 1992; 52(5): 487-495.
50. Adams M, Pieniaszek HJ, Jr, Gammaitoni AR, et al.: Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways. J Clin Pharmacol. 2005; 45(3): 337-345.
51. American Academy of Pain Medicine, American Pain Society, American Society of Addiction Medicine: Definitions related to the use of opioids for the treatment of pain: A consensus document from the American Academy of Pain Medicine the American Pain Society, and the American Society of Addiction Medicine. Glenview, IL: 2001.
52. Reisfield GM, Bertholf R, Barkin RL, et al.: Urine drug test interpretation: what do physicians know? J Opioid Manag. 2007; 3(2): 80-86.
53. Matsumoto AK, Babul N, Ahdieh H: Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial. Pain Med. 2005; 6(5): 357-366.
54. Kivitz A, Ma C, Ahdieh H, et al.: A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee. Clin Ther. 2006; 28: 352-364.
55. Gabrait NY, Dvergsten C, Ahdieh H: Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: A randomized controlled study. Curr Med Res Opin. 2004; 20(6): 911-918.
56. Hale ME, Dvergsten C, Gimbel J: Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study. J Pain. 2005; 6(1): 21-28.
57. Hale ME, Ahdieh H, Ma T, et al.: Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: A 12-week, randomized, double-blind, placebo-controlled study. J Pain. 2007; 8(2): 175-184.
58. Katz J, Rauck R, Ahdieh H, et al.: A 12-week randomized placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. Curr Med Res Opin. 2007; 23(1): 117-128.
59. Sloan P, Slatkin N, Ahdieh H: Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: A pilot study. Support Care Cancer. 2005; 13(1): 57-65.
60. McIlwain H, Ahdieh H: Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: a one-year study. Am J Ther. 2005; 12(2): 106-112.
61. Ahdieh H, Kerwin R, Yuen F: Low dose titration with oxymorphone extended release to achieve effective long-term treatment of moderate to severe pain in opioid-naive patients. Presented at: American Academy of Physician Assistants 34th Annual Physician Assistant Conference; May 27-June 1, 2006; San Francisco, CA.
62. Kalso E, Edwards JE, Moore RA, et al.: Opioids in chronic non-cancer pain: Systematic review of efficacy and safety. Pain. 2004; 112(3): 372-380.
63. Adams D, Royal M, Jenson MG, et al.: Retrospective assessment of frequency of dosing of sustained release opiate preparations. Presented at American Pain Society 21st Scientific Meeting, March 14-17, 2002; Baltimore, MD. American Pain Society 2002 Abstract Database. Available at http://www.ampainsoc.org/db2/abstract/view?poster_id=1088. Accessed December 6, 2005.